General Announcement::Data on Glenmark Pharmaceuticals GBR 830

Issuer & Securities

Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PH US$200M4.5%210802 - XS1456577334 - 4N4B
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
19-Oct-2018 11:55:20
Status
New
Announcement Sub Title
Data on Glenmark Pharmaceuticals GBR 830
Announcement Reference
SG181019OTHRNWJJ
Submitted By (Co./ Ind. Name)
Glenmark Pharmaceuticals Limited
Designation
Company Secretary & Compliance Officer
Effective Date and Time of the event
19/10/2018 09:22:00
Description (Please provide a detailed description of the event in the box below)
Data on Glenmark Pharmaceuticals GBR 830, a First-in-Class, Investigational, Anti-OX40 Monoclonal Antibody in Development for the Treatment of Moderate-to-Severe Atopic Dermatitis, to be Presented at the Fall Clinical Dermatology Conference

Attachments

PR_19102018.pdf
Total size =210K